Centene Corporation Company Profile (NYSE:CNC)

Centene Corporation trades on the New York Stock Exchange (NYSE) under the ticker symbol "CNC."

Centene Corporation (NYSE:CNC) announced its quarterly earnings results on Tuesday, July, 25th. The company reported $1.59 earnings per share for the quarter, beating the Zacks' consensus estimate of $1.30 by $0.29. The firm had revenue of $11.95 billion for the quarter, compared to analyst estimates of $11.69 billion. Centene Corporation had a net margin of 1.72% and a return on equity of 14.62%. The business's revenue was up 9.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.29 earnings per share. View Centene Corporation's Earnings History.

Centene Corporation is scheduled to release their next quarterly earnings announcement on Tuesday, October, 24th 2017. View Earnings Estimates for Centene Corporation.

Centene Corporation updated its FY17 earnings guidance on Tuesday, July, 25th. The company provided earnings per share guidance of $4.70-5.06 for the period, compared to the Thomson Reuters consensus estimate of $4.79. The company issued revenue guidance of $46.4-47.2 billion, compared to the consensus revenue estimate of $46.82 billion.

17 equities research analysts have issued 12-month price targets for Centene Corporation's shares. Their forecasts range from $69.00 to $111.00. On average, they anticipate Centene Corporation's share price to reach $91.07 in the next year. View Analyst Ratings for Centene Corporation.

Here are some recent quotes from research analysts about Centene Corporation stock:

• 1. According to Zacks Investment Research, "Year to date, Centene’s shares have outperformed the industry. The company’s strong and consistent performance is likely to have generated confidence among the investors. It has seen substantial inorganic growth in the last five years. The acquisition of Health Net in 2016 bolstered the company’s growth, expansion and asset base. Its solid financial position provides a major boost to its capital deployment initiatives. The company’s strong Managed care segment also contributes to its strong results. The stock has seen the Zacks Consensus Estimate for the current year being revised upward by 3.4% in the last 60 days." (9/15/2017)
• 2. Cantor Fitzgerald analysts commented, "This morning, CNC reported 2Q17 results. Revenue of $11.95 billion was slightly ahead of FactSet consensus. Adjusted EPS was $1.59 vs. our estimate of $1.25 and consensus of $1.30." (7/25/2017)

Some companies that are related to Centene Corporation include Alexion Pharmaceuticals (ALXN), Zoetis (ZTS), McKesson Corporation (MCK), Illumina (ILMN), Fresenius Medical Care Corporation (FMS), Actelion (ALIOF), HCA Holdings (HCA), Essilor International SA (ESLOY), Astellas Pharma (ALPMY), Incyte Corporation (INCY), Edwards Lifesciences Corporation (EW), Zimmer Biomet Holdings (ZBH), C.R. Bard (BCR), Cerner Corporation (CERN), Cardinal Health (CAH), Quintiles Transitional Holdings (Q), AmerisourceBergen Corporation (Holding Co) (ABC) and Teva Pharmaceutical Industries Limited (TEVA).

Centene Corporation's management team includes the folowing people:

• Michael F. Neidorff, Chairman of the Board, President, Chief Executive Officer
• Jeffrey A. Schwaneke CPA, Chief Financial Officer, Executive Vice President, Treasurer
• Keith H. Williamson, Executive Vice President, General Counsel, Secretary
• Christopher D. Bowers, Executive Vice President - Marketing
• Cynthia J. Brinkley, Executive Vice President - Global Corporate Development
• Jesse N. Hunter, Executive Vice President - Products
• Christopher R. Isaak, Senior Vice President, Corporate Controller and Chief Accounting Officer
• Mark J. Brooks, Senior Vice President, Chief Information Officer
• Christopher A. Koster, Senior Vice President - Corporate Services
• Orlando Ayala, Independent Director

Centene Corporation's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include VANGUARD GROUP INC (10.11%), Vanguard Group Inc. (9.70%), BlackRock Inc. (7.74%), Capital World Investors (4.42%), State Street Corp (4.15%) and Wells Fargo & Company MN (2.43%). Company insiders that own Centene Corporation stock include Carol Goldman, Christopher D Bowers, Jeffrey A Schwaneke, Jesse N Hunter, Keith H Williamson, Kenneth Rone Baldwin, Mark J Brooks, Michael F Neidorff, Richard A Gephardt and Robert K Ditmore. View Institutional Ownership Trends for Centene Corporation.

Centene Corporation's stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., American Century Companies Inc., Schroder Investment Management Group, Neuberger Berman Group LLC, William Blair Investment Management LLC, Korea Investment CORP, FMR LLC and BNP Paribas Arbitrage SA. Company insiders that have sold Centene Corporation stock in the last year include Carol Goldman, Christopher D Bowers, Jeffrey A Schwaneke, Jesse N Hunter, Keith H Williamson, Kenneth Rone Baldwin, Mark J Brooks, Michael F Neidorff, Richard A Gephardt and Robert K Ditmore. View Insider Buying and Selling for Centene Corporation.

Centene Corporation's stock was bought by a variety of institutional investors in the last quarter, including Ameriprise Financial Inc., AJO LP, Vanguard Group Inc., Numeric Investors LLC, Wedge Capital Management L L P NC, Wells Fargo & Company MN, Teachers Advisors LLC and HealthCor Management L.P.. View Insider Buying and Selling for Centene Corporation.

Shares of Centene Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Centene Corporation stock can currently be purchased for approximately $89.78.